2025年的短期课程
Monday, 10 November, 2025
SC1: Best Practices and Advanced Applications for Label-Free Interaction Analysis in Therapeutic Antibody Discovery
Yasmina Abdiche, PhD, Senior Vice President, Exploratory Research, OmniAb Inc.
SC2: Best Practices for Targeting GCPRs, Ion Channels, and Transporters with Monoclonal Antibodies
Ross Chambers, PhD, Vice President, Antibody Discovery, Integral Molecular, Inc.
SC3: Developability of Bispecific Antibodies
Nimish Gera, PhD, Vice President, Biologics, Mythic Therapeutics
SC4: In silico and Machine Learning Tools for Antibody Design and Developability Predictions
Rahmad Akbar, PhD, Senior Data Scientist, Antibody Design, Novo Nordisk
Vinodh B. Kurella, PhD, Biotherapeutic Computational Modeler, Takeda Pharmaceuticals, Inc.
Odysseas Vavourakis, Generative Antibody Design, University of Oxford
* 活动内容有可能不事先告知作更动及调整。
会议议程

工程分会

标靶分会

双特异性分会

免疫疗法分会

分析法分会
- Optimisation & Developability
优化和可开发性 - Analytical Characterisation
分析方法的表征 - Protein Stability & Formulation
蛋白质稳定性和配方

表达分会

机器学习分会
